The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Open accessAbstract
BACKGROUND: Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint. METHODS: In a multicentre, 2×2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years with active, previously untreated neovascular age-related macular degeneration and a best corrected distance visual acuity (BCVA) of at least 25 letters from 23 hospitals in the UK. Participants were randomly assigned (1:1:1:1) to intravitreal injections of ranibizumab (0·5 mg) or bevacizumab (1·25 mg) in continuous (every month) or discontinuous (as needed) regimens, with monthly review. Study participants and clinical assessors were masked to drug allocation. Allocation to continuous or discontinuous treatment was masked up to 3 months, at which point investigators and participants were unmasked. The primary outcome was BCVA at 2 years, with a prespecified non-inferiority limit of 3·5 letters. The primary safety outcome was arterial thrombotic event or hospital admission for heart failure. Analyses were by modified intention to treat. This trial is registered, number ISRCTN92166560. FINDINGS: Between March 27, 2008, and Oct 15, 2010, 628 patients underwent randomisation. 18 were withdrawn; 610 received study drugs (314 ranibizumab; 296 bevacizumab) and were included in analyses. 525 participants reached the visit at 2 years: 134 ranibizumab in continuous regimen, 137 ranibizumab in discontinuous regimen, 127 bevacizumab in continuous regimen, and 127 bevacizumab in discontinuous regimen. For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean difference -1·37 letters, 95% CI -3·75 to 1·01; p=0·26). Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1·63 letters, -4·01 to 0·75; p=0·18). Frequency of arterial thrombotic events or hospital admission for heart failure did not differ between groups given ranibizumab (20 [6%] of 314 participants) and bevacizumab (12 [4%] of 296; odds ratio [OR] 1·69, 95% CI 0·80-3·57; p=0·16), or those given continuous (12 [4%] of 308) and discontinuous treatment (20 [7%] of 302; 0·56, 0·27-1·19; p=0·13). Mortality was lower with continuous than discontinuous treatment (OR 0·47, 95% CI 0·22-1·03; p=0·05), but did not differ by drug group (0·96, 0·46-2·02; p=0·91). INTERPRETATION: Ranibizumab and bevacizumab have similar efficacy. Reduction in the frequency of retreatment resulted in a small loss of efficacy irrespective of drug. Safety was worse when treatment was administered discontinuously. These findings highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought. FUNDING: UK National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in the IVAN study, the incidence was similar in eyes treated with ranibizumab (28%) and with bevacizumab (31%; p=0.46)”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“In CATT and all randomized clinical trials of anti-VEGF treatment for neovascular AMD, most of the improvement in mean visual acuity from baseline occurred within the first 3 to 6 months with little erosion of the benefit through 2 years when a fixed schedule of monthly (ranibizumab, bevacizumab, aflibercept) or bi-monthly (aflibercept) treatment was maintained.1,7,9,17,34”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“decreasing the likelihood of a true effect of ranibizumab on development of geographic atrophy.”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“In the IVAN study, 34% of eyes that received continuous (monthly) treatment developed geographic atrophy as compared with 26% in the discontinuous (PRN) group (p=0.03).9”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Cited by
Sorted by citations
Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,154
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,651
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A. J., Gardiner, T. A., Lyons, T. J., Hammes, H., Simó, R., et al. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,202
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Bressler, N. M., Bressler, S. B., Brucker, A. J., Ferris, F. L., Hampton, G. R., Jhaveri, C. D., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.022 · Cited by 1,058
“78 Intraocular pressure elevationz 18 (13) 15 (11) 18 (14) 0.”
Schmidt-Erfurth, U. M., García‐Arumí, J., Bandello, F. M., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J. B., Larsen, M., Tadayoni, R., & Loewenstein, A. (2017) · Ophthalmologica · doi:10.1159/000458539 · Cited by 728
Self-citationMaguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Schmidt-Erfurth, U. M., Chong, V. N., Loewenstein, A., Larsen, M., Souied, E. H., Schlingemann, R. O., Eldem, B. M., Monés, J., Richard, G. W., & Bandello, F. M. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 678
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Ho, A. C., BUSBEE, B. G., Regillo, C. D., Wieland, M. R., Everen, S. A. V., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 594
Deep learning in ophthalmology: The technical and clinical considerations
Ting, D. S. W., Peng, L. H., Varadarajan, A. V., Keane, P. A., Burlina, P., Chiang, M. F., Schmetterer, L. F., Pasquale, L. R., Bressler, N. M., Webster, D. R., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.04.003 · Cited by 566
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Recent developments in age-related macular degeneration: a review
Al-Zamil, W. M., & Yassin, S. A. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143508 · Cited by 425
“134 A meta-analysis evaluating the results of the data from both the CATT and the IVAN trials convincingly demonstrated that bevacizumab was not inferior to ranibizumab in best-corrected VA in patients with wet AMD.”
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
“obtained in PrONTO were not replicated in large-scale prospective trials, and less frequent dosing regimens generally provided inferior functional outcomes (Chakravarthy et al., 2013; Holz et al., 2011; Regillo et al., 2008; Schmidt-Erfurth et al., 2011).”
BackgroundResultBerg, K., Pedersen, T. R., Sandvik, L., & Bragadóttir, R. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.041 · Cited by 400
Avery, R. L., CASTELLARIN, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R. F., Couvillion, S. S., Nasir, M. A., Rabena, M., Le, K. N., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305252 · Cited by 385
Avery, R. L., CASTELLARIN, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R. F., Couvillion, S. S., Nasir, M. A., Rabena, M., Maia, M., et al. (2017) · Retina · doi:10.1097/iae.0000000000001493 · Cited by 360
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A. A., Lim, J. I., Vemulakonda, G. A., & Ying, G. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 367
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W., Ogura, Y., Yeo, I. Y. S., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 345
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K. B., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 280
Mehta, H., Tufail, A., Daïen, V., Lee, A., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 269
“Randomised controlled trials comparing intravitreal ranibizumab and bevacizumab found similar efficacy for the treatment of nAMD (Chakravarthy et al., 2013; Martin et al., 2012).”
BackgroundA new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration
Holz, F. G., Sadda, S. R., Staurenghi, G., Lindner, M., Bird, A. C., Blodi, B. A., Bottoni, F. G., Chakravarthy, U., Chew, E. Y., Csaky, K. G., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.12.002 · Cited by 251
Self-citationClinical pharmacology of intravitreal anti-VEGF drugs
Fogli, S., Re, M. D., Rofi, E., Posarelli, C., Figus, M., & Danesi, R. (2018) · Eye · doi:10.1038/s41433-018-0021-7 · Cited by 238
Avery, R. L., & Gordon, G. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4070 · Cited by 218
Bhisitkul, R. B., Mendes, T. S., Rofagha, S., Enanoria, W., Boyer, D. S., Sadda, S. R., & Zhang, K. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.032 · Cited by 210
Grunwald, J. E., Pistilli, M., Daniel, E., Ying, G.-S., Pan, W., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., Maguire, M. G., & Martin, D. F. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.012 · Cited by 214
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Ricci, F., Bandello, F. M., Navarra, P., Staurenghi, G., Stumpp, M. T., & Zarbin, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218242 · Cited by 222
“The two-year results of the IVAN study confirmed these findings [103].”
BackgroundMethodResultInfluentialRecent developments in the treatment of age-related macular degeneration
Holz, F. G., Schmitz-Valckenberg, S., & Fleckenstein, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71029 · Cited by 207
“64, 65, ISRCTN92166560); however, only an average of four to five injections were actually administered.”
Ciulla, T. A., Hussain, R. M., Pollack, J. S., & Williams, D. F. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.017 · Cited by 205
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Moja, L., Lucenteforte, E., Kwag, K. H., Bertelè, V., Campomori, A., Chakravarthy, U., D’Amico, R., Dickersin, K., Kodjikian, L., Lindsley, K. B., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011230.pub2 · Cited by 190
Self-citationRakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00345-1 · Cited by 189
Targeting VEGF in eye neovascularization: What's new?
Amadio, M., Govoni, S. M., & Pascale, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.027 · Cited by 180
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.028 · Cited by 173
Berg, K., Hadzalic, E., Gjertsen, I. K., Forsaa, V. A., Berger, L. H., Kinge, B., Henschien, H. J., Fossen, K., Markovic, S., Pedersen, T. R., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.018 · Cited by 164
Wecker, T., Ehlken, C., Bühler, A., Lange, C., Agostini, H. T., Böhringer, D., & Stahl, A. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308668 · Cited by 159
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Wang, L., Liu, W., Broussy, S., Han, B., & Fang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1307860 · Cited by 169
Doubly blind: a systematic review of gender in randomised controlled trials
Phillips, S. P., & Hamberg, K. (2016) · Global Health Action · doi:10.3402/gha.v9.29597 · Cited by 158
“Byrd (industry) (24) Comparison of two doses of a drug to treat CLL Outcome described drug as effective but without a control group N 85 Women 24% Protocol changed during study Preponderance of men 34% attrition from study unclear if they dropped out or were removed or whether they were included in analyses Endpoints…”
BackgroundMyopic choroidal neovascularisation: current concepts and update on clinical management
Wong, T. Y., Ohno‐Matsui, K., Leveziel, N., Holz, F. G., Lai, T. Y. Y., Yu, H. G., Lanzetta, P., Chen, Y., & Tufail, A. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305131 · Cited by 154
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration
Jaffe, G. J., Ciulla, T. A., Ciardella, A. P., Devin, F., Dugel, P. U., Eandi, C. M., Masonson, H., Monés, J., Pearlman, J. A., Maftouhi, M. Q.-E., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.10.010 · Cited by 153
“, less than monthly or bimonthly) dosing results in worse visual outcomes compared with continuous doing.(1,3) Furthermore, the ceiling of anti-VEGF monotherapy has been reached with currently available agents; despite increased anti-VEGF dosage or various regimens, no additional benefit is evident.”
BackgroundReticular pseudodrusen: A critical phenotype in age-related macular degeneration
Wu, Z., Fletcher, E. L., Kumar, H., Greferath, U., & Guymer, R. H. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101017 · Cited by 147
Evans, R. N., Reeves, B. C., Maguire, M. G., Martin, D. F., Muldrew, A., Peto, T., Rogers, C., & Chakravarthy, U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.3001 · Cited by 145
Self-citationPugazhendhi, A., Hubbell, M., Jairam, M. P., & Ambati, B. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031170 · Cited by 148
Genome Editing Abrogates Angiogenesis in Vivo
Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., Xiao, R., Vandenberghe, L., Zhang, F., D’Amore, P. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00140-3 · Cited by 142
Aflibercept for neovascular age-related macular degeneration
Sarwar, S., Clearfield, E., Soliman, M. K., Sadiq, M. A., Baldwin, A. J., Hanout, M., Agarwal, A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011346.pub2 · Cited by 142
Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration
Sadda, S. R., Tuomi, L. L., Ding, B., Fung, A. E., & Hopkins, J. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.12.026 · Cited by 155
Li, E., Donati, S., Lindsley, K. B., Krzystolik, M. G., & Virgili, G. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012208.pub2 · Cited by 143
Wu, W.-C., Shih, C.-P., Lien, R., Wang, N., Chen, Y., Chao, A., Chen, K., Chen, T., Hwang, Y., & Lai, C. (2016) · Retina · doi:10.1097/iae.0000000000001209 · Cited by 137
Wykoff, C. C., Ou, W. C., Brown, D. M., Croft, D. E., Wang, R., Payne, J. F., Clark, W. L., Abdelfattah, N. S., & Sadda, S. R. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2016.12.004 · Cited by 133
Waldstein, S. M., Wright, J., Warburton, J., Margaron, P., Simader, C., & Schmidt-Erfurth, U. M. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.013 · Cited by 132
Gemenetzi, M. K., Lotery, A. J., & Patel, P. J. (2016) · Eye · doi:10.1038/eye.2016.208 · Cited by 134
Self-citationHolz, F. G., Tadayoni, R., Beatty, S., Berger, A. R., Cereda, M. G., Hykin, P. G., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308166 · Cited by 125
Wykoff, C. C., Clark, W. L., Nielsen, J. S., Brill, J. V., Greene, L. S., & Heggen, C. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.2-a.s3 · Cited by 127
Anti-VEGF Therapy and the Retina: An Update
Tah, V., Orlans, H. O., Hyer, J. N., Casswell, E. J., Din, N., Shanmuganathan, V. S., Ramskold, L., & Pasu, S. (2015) · Journal of Ophthalmology · doi:10.1155/2015/627674 · Cited by 130
“…groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters for different dosing regimens (0.5mg every 4weeks, 2mg every 4weeks, 2mg every 8weeks after 3 initial monthly doses, and 2mg as needed after 3 initial monthly doses, resp.) versus −1.3 letters for the laser group (𝑃 ≤ 0.0001 versus laser).”
BackgroundInfluentialManagement of pseudophakic cystoid macular edema
Guo, S., Patel, S. N., Baumrind, B. R., Johnson, K. S., Levinsohn, D., Marcus, E., Tannen, B. L., Roy, M. S., Bhagat, N., & Zarbin, M. A. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.08.005 · Cited by 120
Age-Related Macular Degeneration
Mehta, S. (2015) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2015.05.009 · Cited by 126
“The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and Inhibit VEGF in the Age-Related Choroidal Neovascularization trial (IVAN) were large clinical trials comparing ranibizumab and bevacizumab in the treatment of wet AMD.(24,25) Both studies showed that patients undergoing treatment with rani…”
ResultBoyle, J., Vukicevic, M., Koklanis, K., Itsiopoulos, C., & Rees, G. (2018) · Psychology, Health & Medicine · doi:10.1080/13548506.2016.1274040 · Cited by 119
“Psychometric evaluation was later conducted in the Inhibit VEGF in Age-related Choroidal Neovascularisation (IVAN) clinical trial (Chakravarthy et al., 2012, 2013).”
MethodCheung, C. M. G., & Wong, T. Y. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12227 · Cited by 122
Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration
Schaal, K. B., Rosenfeld, P. J., Gregori, G., Yehoshua, Z., & Feuer, W. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.034 · Cited by 115
Rayess, N., Houston, S. K. S., Gupta, O. P., Ho, A. C., & Regillo, C. D. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.09.011 · Cited by 115
Ciulla, T. A., Huang, F., Westby, K., Williams, D. F., Zaveri, S., & Patel, S. C. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.01.006 · Cited by 115
Hykin, P. G., Prevost, A. T., Vasconcelos, J. C., Murphy, C., Kelly, J., Ramu, J., Hounsome, B., Yang, Y. C., Harding, S. P., Lotery, A. J., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.3305 · Cited by 112
Self-citationMonés, J., Singh, R. P., Bandello, F., Souied, E., Liu, X., & Gale, R. (2020) · Ophthalmologica · doi:10.1159/000502747 · Cited by 110
Munk, M. R., Ceklic, L., Ebneter, A., Huf, W., Wolf, S., & Zinkernagel, M. S. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13157 · Cited by 107
Waldstein, S. M., Philip, A.-M., Leitner, R., Simader, C., Langs, G., Gerendas, B. S., & Schmidt-Erfurth, U. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4948 · Cited by 110
Polat, O., İnan, S., Özcan, S., Doğan, M., Küsbeci, T., Yavaş, G. F., & İnan, Ü. U. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.28003 · Cited by 107
Cho, H. J., Yoo, S. G., Kim, H. S., Kim, J. H., Kim, C. G., Lee, T. G., & Kim, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.10.035 · Cited by 102
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Dakin, H., Culliford, L. A., Scott, L. J., Nash, R. L., Taylor, J., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19780 · Cited by 100
Self-citationBarthelmes, D., Nguyen, V., Daïen, V., Campain, A. E., Walton, R., Guymer, R. H., Morlet, N., Hunyor, A. P., Essex, R. W., Arnold, J., et al. (2017) · Retina · doi:10.1097/iae.0000000000001496 · Cited by 98
Macular Atrophy in Neovascular Age-Related Macular Degeneration
Gillies, M. C., Hunyor, A. P., Arnold, J., Guymer, R. H., Wolf, S., Pecheur, F. L., Munk, M. R., & McAllister, I. L. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.08.023 · Cited by 92
“141 139 Yes 1 (1) 1 (1) No 8 (6) 8 (6) N/A 132 (93) 130 (93) Inner subfield, no.”
InfluentialLin, J. B., Tsubota, K., & Apte, R. S. (2016) · npj Aging and Mechanisms of Disease · doi:10.1038/npjamd.2016.3 · Cited by 90
ElSheikh, R. H., Chauhan, M. Z., & Sallam, A. B. (2022) · Biomolecules · doi:10.3390/biom12111629 · Cited by 96
“The frequency of arterial thrombotic events and the overall safety profile were similar in both groups [32].”
BackgroundHolekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.12.018 · Cited by 88
Hussain, R. M., & Ciulla, T. A. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1362390 · Cited by 91
Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
Tan, C. S., Ngo, W. K., Chay, I. W., Ting, D. S., & Sadda, S. R. (2022) · Clinical ophthalmology · doi:10.2147/opth.s231913 · Cited by 94
“26).(17) The bevacizumab group had a mean gain of 4.”
BackgroundRosenfeld, P. J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19969 · Cited by 90
“The formation of macular atrophy after anti-VEGF therapy was confirmed in the CATT and IVAN trials after 2 years, and in these trials, the monthly dosing groups had a higher incidence of macular atrophy compared with the discontinuous treatment groups.(25,43,44) While this observation has raised questions about whethe…”
ResultRosenberg, D., Deonarain, D. M., Gould, J., Sothivannan, A., Phillips, M., Sarohia, G. S., Sivaprasad, S., Wykoff, C. C., Cheung, C. M. G., Sarraf, D., et al. (2022) · Eye · doi:10.1038/s41433-022-02020-7 · Cited by 91
Bhisitkul, R. B., Desai, S. J., Boyer, D. S., Sadda, S. R., & Zhang, K. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.033 · Cited by 90
Vedula, S. S., & Krzystolik, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub2 · Cited by 87
Fauser, S., Schwabecker, V., & Muether, P. S. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.025 · Cited by 85
Chandra, S., Arpa, C., Menon, D., Khalid, H., HAMILTON, R. D., Nicholson, L., Pal, B., Fasolo, S., Hykin, P. G., Keane, P. A., et al. (2020) · Eye · doi:10.1038/s41433-020-0764-9 · Cited by 88
“At the end of 2 years, the risk of developing geographic atrophy was reported as 34% with monthly injections versus 26% with PRN administration [16].”
BackgroundZehden, J., Mortensen, X. M., Reddy, A. K., & Zhang, A. Y. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01491-y · Cited by 90
Lipécz, Á., Miller, L. R., Kovács, I., Czakó, C. N., Csípő, T., Baffi, J., Csiszár, A., Tarantini, S., Ungvari, Z. I., Yabluchanskiy, A., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00138-3 · Cited by 87
Avery, R. L. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303844 · Cited by 85
Endothelial Progenitor Cells in Diabetic Retinopathy
Lois, N., McCarter, R. V., Oâ€TMNeill, C., Medina, R. J., & Stitt, A. W. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00044 · Cited by 84
Dakin, H., Wordsworth, S., Rogers, C. A., Abangma, G., Raftery, J. P., Harding, S. P., Lotery, A. J., Downes, S. M., Chakravarthy, U., Reeves, B. C., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005094 · Cited by 85
“and bevacizumab produced similar improvements in visual function, with no significant difference in arteriothrombotic events or hospital admissions for heart failure, which have previously been linked with anti-VEGF therapy.(5) IVAN also compared discontinuous (as-needed) treatment against continuous monthly injec-”
Self-citationIntravitreal injections: past trends and future projections within a UK tertiary hospital
Chopra, R., Preston, G. C., Keenan, T. D. L., Mulholland, P., Patel, P. J., Balaskas, K., Hamilton, R. D., & Keane, P. A. (2022) · Eye · doi:10.1038/s41433-021-01646-3 · Cited by 83
Chakravarthy, U., Bailey, C., Brown, D. M., Campochiaro, P. A., Chittum, M. E., Csaky, K. G., Tufail, A., Yates, P., Cech, P. G., Giraudon, M., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.003 · Cited by 82
Self-citationPham, B., Thomas, S. M., Lillie, E., Lee, T., Hamid, J. S., Richter, T. A., Janoudi, G., Agarwal, A., Sharpe, J. P., Scott, A., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022031 · Cited by 84
Okada, M., Kandasamy, R., Chong, E. W. T., McGuiness, M. B., & Guymer, R. H. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.05.026 · Cited by 82
Jaffe, G. J., Kaiser, P. K., Thompson, D. E., Gibson, A., Saroj, N., Vitti, R., Berliner, A. J., & Heier, J. S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.05.016 · Cited by 79
Schauwvlieghe, A.-S. M. E., Dijkman, G., Hooymans, J. M. M., Verbraak, F. D., Hoyng, C. B., Dijkgraaf, M. G. W., Pető, T., Vingerling, J. R., & Schlingemann, R. O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153052 · Cited by 87
“Consistent with the results of CATT, IVAN and MANTA studies, the mean treatment outcome with bevacizumab showed slightly less gain in BCVA, but of a magnitude that can be regarded as clinically insignificant [4,6,7].”
BackgroundMethodResultInfluentialHutton, D. W., Newman-Casey, P. A., Tavag, M., Zacks, D. N., & Stein, J. D. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.0832 · Cited by 79
The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer
Zhu, X., & Zhou, W. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00159 · Cited by 84
AIF-independent parthanatos in the pathogenesis of dry age-related macular degeneration
Jang, K.-H., Do, Y., Son, D., Son, E., Choi, J., & Kim, E. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.437 · Cited by 77
“Collectively, we report that AIF-independent PARP-1-dependent necrosis constitutes a major mechanism of RPE cell death leading to retinal degeneration in dry AMD.”
BackgroundInfluentialConstable, I. J., Lai, C.-M., Magno, A. L., French, M. A., Barone, S. B., Schwartz, S. D., Blumenkranz, M. S., Degli-Esposti, M. A., & Rakoczy, E. P. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.02.018 · Cited by 76
Zarbin, M. A., Sugino, I. K., & Townes‐Anderson, E. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0282 · Cited by 77
Mantel, I., Niderprim, S.-A., Gianniou, C., Deli, A., & Ambresin, A. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304556 · Cited by 75
Raftery, J. P., Young, A. J., Stanton, L., Milne, R., Cook, A., Turner, D., & Davidson, P. (2015) · Health Technology Assessment · doi:10.3310/hta19110 · Cited by 73
Martín, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.019 · Cited by 76
Metadata
- Authors
- Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Chakravarthy, Usha
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 382
- Issue
- 9900
- Pages
- 1258-1267
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2154073405
- Cited by
- 748
- References
- 45
- Citations by year
- 2026: 13 · 2025: 36 · 2024: 36 · 2023: 36 · 2022: 33 · 2021: 84 · 2020: 66 · 2019: 44 · 2018: 74 · 2017: 66 · 2016: 90 · 2015: 77 · 2014: 75 · 2013: 13
- FWCI
- 84.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, cc-by-nc-sa)
- Bristol Research (University of Bristol) (submittedVersion, cc-by-nc-sa)
- ePrints Soton (University of Southampton) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institute for Health and Care Research (07/36/01)
- Health Technology Assessment Programme (07/36/01, /36/01)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, bevacizumab, ranibizumab, anti-VEGF therapy, intravitreal injection, treatment regimen comparison, best-corrected visual acuity, non-inferiority, arterial thrombotic events, long-term outcomes
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Female, Humans, Male, Middle Aged, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
